WSTAM
VYGR icon

Wilbanks Smith & Thomas Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$2K – 1292
2018
Q3 		$2K Buy
+100
New +$1.92K ﹤0.01% 1442

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's VYGR Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Voyager Therapeutics (VYGR) in Q4 2018, closing a stake of 100 shares — an estimated $2K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in VYGR in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 116 funds tracked by Wall St. Rank hold VYGR as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Voyager Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 100 Voyager Therapeutics shares in Q4 2018, an estimated $2K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Voyager Therapeutics in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Voyager Therapeutics position peaked at $2K in Q3 2018.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.